Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you have your tax strategy set as (LIFO- last in first out), those recently 50 shares that you purchased at .09 will be the first to sell, so not a wash because you're selling them at 12.
You are original hundred shares are left untouched.
It goes the same as if you bought those hundred shares at $0.80, and you finally got out of biopharmx at $0.60 but never bought back in within the 30-day period to trigger a wash sale, then technically you still get a tax write-off coming to you because those shares originally were purchased above the $0.60 sale price at .80.
https://finance.zacks.com/determine-shares-sell-fifo-lifo-9766.html
emz, question for you...
Now that you're long (congrats by the way), are you aware of changes you can make to your tax strategy in your brokerage account? (LIFO) So you can flip your newest shares and leave your older long term shares sit. This way you can flip your latest short term shares and leave the big investment alone.
I personally have a nice old chunk sitting long and know my limit of flippable shares that I continuously add to my portfolio here.
I appreciate your support in BPMX and just wanted to share some helpful info on building up your portfolio.
Broke through AH! $.015
I agree! It's definitely testing in AH! Definitely looking good here!
Avalon is Live
https://livestream.com/nasdaq/live
Looks like .145 will be the resistance. Tried breaking through two times. Don't think that there's enough strength today.
3.18, move on 100 shares. Hmm, I'll take it! Keep inching up!
Come on! Break that 50day sitting at .1459, then we're really off and running!
L2 has peak sell orders sitting at .1794
(MAXM,NITE,ROTH, about 9)
A lot of interest on this one today! Great start to the week!
A close above 3.15 would make things look better!
It tested 3.15 on 4/10/18 and 12/19/18 so I like to see it break past that resistance.
I know the feeling, lol.
As for a fairly new chart here, it looks like it's turning bullish! 50 day above the 200, price riding above that 50day! MACD moving up! Volume increasing!
I'd say that this thing looks ready to rally!
Let's hope it keeps moving in this direction so I can stay around for a bit, lol.
So you're not moderating the board here? I see this ticker hasn't gained popularity on other message boards yet either. Hopefully your patience will pay off and that we're here before a nice run up!
I've been over at BPMX for years investing. Price is still low over there and we're expecting a good year. Give em a look.
GLTY!
Looks like you've been here for awhile. Any good things coming up that you know about? I know that they're ringing the closing bell today. I see that there has been some salary increases. Something brewing?
Nice start to the week! Avg. Vol. 2.39 so it's looking pretty good today!
They are on the participation list.
Scroll down to the "B's"
Link
Just saying, we might have to dig around a bit while we wait for something solid to be announced.
We came from a board/president of BioPharmX that was spending money without regard, hence why we are, where we are! (stock price)
Now we have a CEO running the company that's cutting expenses and is here to do what we all want! Make this company valuable!
Tierney isn't here to pump the price on fluff news. His silence actually gives me confidence in his role in saving this company from the damage Anja has left us with.
GLTY figaruch! We're going to see changes here this year!
No pumping from Tierney as new CEO of BioPharmX so one has to dig deeper for DD!
This week is happening in San Francisco for members of the healthcare investment community!
* Solebury Trout Annual 1x1 Management Access Event Link
* 37th Annual J.P. Morgan
HEALTHCARE CONFERENCE Link
Both events happening the same week in San Francisco January 7 - 10, 2019
"I have consulted with several key opinion leaders and am encouraged by the significant potential of the HyantX™ delivery system and its late-stage development assets, BPX-01 and BPX-04. I have also met and spoken with several key stakeholders to understand the concerns and challenges the company faces as it embarks on a new chapter of operational execution to deliver long-term value to its shareholders."
"While strategic partnering has been and continues to be an attractive option for advancing clinical development, regulatory submission, and commercial launch for BPX-01 for acne, a strategic review of the program is ongoing to determine our ultimate go-forward strategy. We want to consider all options before committing the company to a single course of action. We will provide an update when that strategy is defined."
David S. Tierney (CEO Letter)
There hasn't been any official announcement from BioPharmX on these conferences.
Statistically, January is BioPharmX's month for gains!
https://stockcharts.com/freecharts/seasonality.php?symbol=BPMX
Hopefully Tierney can make some deals this week at the investors conference. Now that the holidays are over, time to get down to business!
Hey, wanted to share with you. Check out this newly NASDAQ listed company. Might be building up to something. Google search for the latest news that has been going on with them. As newly-listed, might be able to get in before a run. At least keep on watch! (AVCO)
GLTY this year!
Took up a position here today. Things look like they're about to get interesting!
Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy
FREEHOLD, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that the Company and its wholly owned subsidiary, Avactis Biosciences, have entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies. These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique “safety-switch" mechanisms. Based on Avalon’s extensive hospital network for cellular therapy, together with the Company’s established GMP bio-production facility in China (Epicon Biotech, Nanjing), this joint venture allows Avalon to accelerate the clinical development of more efficacious and safer CAR-T/CAR-NK therapies, such as those developed by Arbele.
“We are very excited to establish this joint venture with Arbele Limited to accelerate our clinical programs in cellular therapy,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp. “Arbele’s strong proprietary technology platform in designing and production of non-viral, transposon-engineered, multi-targeted CAR will allow us to generate next-generation, better and safer CAR-T and CAR-NK cellular therapeutics. This joint venture will strengthen our core technological capabilities, enrich our intellectual properties, as well as further establish our leadership in the field of cellular immunotherapy,” added Dr. Jin.
About Arbele Limited
Arbele Limited, founded by industry veterans from Roche, Johnson & Johnson and ICOS Corporation, is a biopharmaceutical company focusing on acceleration and expansion of immunotherapy technology and product development to treat advanced stages of cancers, including those most prevalent in the USA, Australia and the Asia-Pacific region. Arbele Limited has headquarters located in the Hong Kong Science and Technology Park, with its state-of-the-art research hub, Arbele Corp., located in Seattle, WA. Arbele Limited currently holds multiple promising “first-in-class” immuno-oncology candidates (including monoclonal and bi-specific antibodies) within its pipeline. Notably, Arbele’s unique non-viral, transposon-based T cell engineering technology is an exceptional system for rapid delivery of CAR-T cell therapeutics. Later in 2019, phase I clinical studies will be conducted in Australia for refractory or advanced gastrointestinal cancers (including colon, stomach and pancreatic), as well as via joint venture with Avalon GloboCare Corp. for clinical development of CAR-T cellular therapy in China.
Link-here
Fighting it's way back up. Investment meetings next week!
How about that volume? Definitely interesting.
Hope you have a great 2019!
Right back at you! Happy New Year!
In-depth review of BPX-01
BioPharmX BPMX BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris
Read full in-depth article in link here
* In Study 1, BPX-01 treatment reduced P. acnes colonization by 90.9 percent, which exceeded the reduction in the vehicle control group
* In Study 2, treatment with BPX-01 2% reduced the number of inflammatory lesions by 58.5 percent, exceeding the reduction in the vehicle control group
* There was a statistically significant decrease in P. acnes during the four weeks of BPX-01 1% treatment
* When asked, “Would you consider using the study medication again?,” 86.2 percent of subjects in the BPX-01 1% group and 81.0 percent in the 2% group answered affirmatively
* Subjects also reported a high degree of satisfaction with using the product and its treatment results.
* This treatment might provide an effective new option with a favorable safety profile, a potential for high patient adherence, and avoidance of AEs associated with oral minocycline use.
HYANTX Update!
On Tuesday, December 18, 2018, status on the HYANTX trademark changed to PUBLISHED FOR OPPOSITION.
After your trademark application has been reviewed and approved by an examining attorney, the mark will be published for opposition, which means that the trademark opposition period starts. The trademark opposition period is a period of thirty days when anyone with a real interest in the proceeding can oppose the trademark application and attempt to stop the trademark from being registered. The mark is published in the Original Gazette, an online USPTO publication that contains all of the trademarks that have been published for opposition. If no opposition is filed or if the opposition is unsuccessful, the application enters the next stage of the registration process.
BioPharmX has developed the HyantX™ delivery system, a novel anhydrous topical delivery system for hydrophilic molecules. The HyantX system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. This delivery system is being developed to carry a variety of active ingredients – and even combinations of actives – into the skin. Research has shown the delivery system may allow for maximum solubility for multiple actives, which is intended to lead to enhanced skin penetration and increased efficacy and tolerability, has antibacterial properties, and hydrates the skin, making the delivery system a valuable asset in pipeline development and strategic partnering.
The first molecule being developed using this delivery system is minocycline for both acne and rosacea indications. Minocycline was selected as the first API as it is the most commonly prescribed oral antibiotic for the treatment of these conditions due to its high effectiveness, anti-inflammatory properties, and relatively low antibiotic resistance rate.
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
GlobeNewswire
West Logo
Search
Contact Us
REGISTER
SIGN IN
ENGLISH
FRANÇAIS
Foamix, Ltd. logo
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
December 21, 2018 07:00 ET | Source: Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older.
“Submission of this NDA is yet another important milestone for Foamix, and potentially brings us one step further to commercial launch of FMX101,” commented David Domzalski, Chief Executive Officer. “We are making this submission following successful efficacy and safety outcomes in our Phase 3 program for FMX101 and incorporating guidance received from the FDA in a Type B pre-NDA meeting held earlier in 2018. We look forward to working with the Agency in its review of our application.”
The NDA submission is supported by the previously communicated results from two Phase 3 trials, FX2014-05 and FX2017-22. In these trials, FMX101 met both co-primary endpoints, demonstrating statistically significant improvements in inflammatory lesion count and Investigator Global Assessment (IGA) treatment success. In these trials, the safety profile of FMX101 was generally favorable and consistent throughout the clinical development program. The NDA submission also incorporates information on chemistry manufacturing and controls, and data from non-clinical toxicology studies on FMX101.
“The comprehensive body of clinical data we have generated with FMX101 suggest that it may offer patients an efficacious treatment in a convenient and well tolerated topical foam formulation,” stated Iain A. Stuart, Ph.D., Senior Vice President, Research & Development, Foamix. “If approved, FMX101 has the potential to address a significant unmet need in the treatment of moderate-to-severe acne, which remains a difficult to treat condition.”
Lonely, I'm so lonely ??... ha ha, yeah, this has been my investment for a long time now.
It's unfortunate that this amazing product
(BPX-01) has been dragging along due to the previous greedy mismanaged president and board of directors. So much time and money was wasted here because of them.
There is full and complete confidence in Dr Tierney on getting this company back on track.
Appreciate your enthusiasm lately.
Rest assured Dr. T. is working on future funding.
NYSE Regulation reviewed the Company's plan to regain compliance with the continued listing standards and granted a plan period through September 24, 2019.
MENLO PARK, Calif., Dec. 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on December 17, 2018 from the NYSE American LLC (the “NYSE American”) that the Company is not in compliance with the stockholders' equity requirements set forth in Section 1003(a)(i) and Section 1003(a)(ii) of the NYSE American Company Guide. The Company reported stockholders' equity of $0.6 million as of October 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018. The continued listing standards require listed companies to maintain stockholders' equity of $2.0 million or more if they have reported losses from continuing operations and/or net losses in their three most recent fiscal years. As previously announced, NYSE Regulation reviewed the Company's plan to regain compliance with the continued listing standards and granted a plan period through September 24, 2019.
The Company's common stock will continue to be listed and traded on NYSE American during the plan period, subject to the Company's compliance with NYSE American's other applicable continued listing standards. The letter does not affect the company's business operations or its Securities and Exchange Commission reporting requirements.
Stock is not going to stay at this low level. Day trader's will be running this up to the 50 day soon.
Just look at this chart. Dipped and recovered before that big run on the new CEO news back in Sept. We will be getting another day trader's run soon but we definitely need company news to really get this thing running. In the meantime, scoop up these cheapies while the RSI is buried in oversold territory.
BioPharmX Corp (BPMX) Gets a Buy Rating from Maxim Group
In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (BPMX), with a price target of $1. The company’s shares closed yesterday at $0.16.
Vendetti observed:
“Yesterday, after the Market close, BPMX reported a F3Q19 (Sep) GAAP loss per share inline with both our estimate and consensus.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.4% and a 48.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
The the analyst consensus on BioPharmX Corp is currently a Hold rating.
Based on BioPharmX Corp’s latest earnings release for the quarter ending July 31, the company reported a quarterly GAAP net loss of $4.41 million. In comparison, last year the company had a GAAP net loss of $3.71 million.
https://www.google.com/amp/s/www.smarteranalyst.com/brief/biopharmx-corp-bpmx-gets-a-buy-rating-from-maxim-group-2/amp/
Letter from the CEO
December 6, 2018
Dear BioPharmX Shareholders,
I would like to introduce myself as the new CEO of BioPharmX. I was recruited by the Board of Directors because of my significant experience leading pharmaceutical and medical device companies through the product development process to FDA approval and, ultimately, commercial launch. Prior to joining BioPharmX, I served as President/CEO at a number of public and private companies, leading those organizations through three NDA approvals, one PMA approval and three successful company exits via M&A. Most recently I served as CEO of Icon Bioscience, an ophthalmology drug delivery company. Before its merger with EyePoint Pharmaceuticals in March 2018, I led the Icon team in the development and February 2018 FDA approval for the drug DEXYCU, a dexamethasone intraocular suspension to treat post-cataract surgery inflammation.
Since joining BioPharmX a little over two months ago, I have focused my efforts on understanding and evaluating the company’s technologies, including the Research & Development (R&D) and Chemistry, Manufacturing and Controls (CMC) work that has been conducted to date, and its capabilities and resources to execute on our drug development strategy. As part of my evaluation, I have consulted with several key opinion leaders and am encouraged by the significant potential of the HyantX™ delivery system and its late-stage development assets, BPX-01 and BPX-04. I have also met and spoken with several key stakeholders to understand the concerns and challenges the company faces as it embarks on a new chapter of operational execution to deliver long-term value to its shareholders.
Based on these discussions and my assessment, we have already taken strategic steps to focus BioPharmX on becoming a high-value dermatology company:
* Following a thorough pipeline review, we streamlined our pipeline strategy to focus exclusively on development candidates based on our HyantX delivery system and discontinued non-core development programs. It is imperative that we focus efforts and resources on programs that promise the highest clinical value and near-term visibility.
* After reviewing spending and resource allocation, we initiated a reduction in workforce in mid-November to rightsize the company to focus our resources on core programs and reduce non-essential costs. The headcount reduction, coupled with moving our R&D facility to a lower-cost location in San Jose, CA, will represent annual savings to the company in excess of $2 million a year.
BPX-04 for the treatment of papulopustular rosacea serves as an example of the focused and disciplined execution against near-term milestones that I plan for the company. We recently initiated a phase 2b study of the product and look forward to updating shareholders on this program with topline data expected mid-2019.
Our operational focus is on the ongoing clinical study in rosacea and CMC development in preparation for phase 3. However, I also want to take this opportunity to address concerns surrounding earlier discussions of a partnership for BPX-01 for acne and maintaining compliance with the New York Stock Exchange.
While strategic partnering has been and continues to be an attractive option for advancing clinical development, regulatory submission, and commercial launch for BPX-01 for acne, a strategic review of the program is ongoing to determine our ultimate go-forward strategy. We want to consider all options before committing the company to a single course of action. We will provide an update when that strategy is defined.
Maintaining compliance with the NYSE American continued listing standards is of paramount importance and the company is working with NYSE Regulation to restore full compliance.
In closing, I am very excited for the opportunity to lead the BioPharmX team and look forward to realizing the value associated with our unique delivery technology. Additionally, I would like to thank the Board, who shares our long-term vision for pipeline advancement and disciplined growth strategies, and our shareholders, who are placing their trust in me as we look toward the future. I look forward to a successful 2019.
With warm regards,
David S. Tierney, M.D.
President & CEO
https://biopharmx.investorroom.com/shareholderletter
Best-in-class topical treatment for acne!
"if the BPX-01 Phase 2 study is successful, the drug could potentially "become the best-in-class topical treatment for acne." To do so, however, it will need to meet, as its secondary endpoint, a two-grade reduction in Investigator's Global Assessment."
Read all about it here
BPX-01: "found that female subjects outperformed the overall study population in the Investigator Global Assessment (IGA) outcomes"
In female subjects with a baseline IGA score of 3 or 4 (moderate-to-severe), 29.2% achieved a two-grade reduction to clear or almost clear while 25% of the total ITT population achieved this reduction. In female subjects with a baseline IGA score of 3 (moderate only), 31.8% of subjects achieved a two-grade reduction to clear or almost clear.
Read all about it here
Substantially Undervalued
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Foamix Pharmaceuticals to $12 from $11 citing the positive top-line results from two pivotal Phase 3 clinical trials of FMX103 for the treatment of moderate-to-severe papulopustular rosacea. The analyst believes the high level of statistical significance underscores the degree of efficacy observed. He reiterates a Buy rating on Foamix and says the stock remains "substantially undervalued."
I agree with you there! The start of P3 for BPX-01 and completion of BPX-04 P2 will give us the best chance of getting us on track for that goal.
If .02¢ excites you, we should be testing .18 here soon. (50MA)
IDK, I wouldn't get to excited on movement tomorrow in regards to today's ER. No movement in after hours is the telltale sign.
The next big move will come when the company secures funding. Hopefully that's in the cards soon! My gut feeling tells me that they will just finish this year out before securing funding for 2019.
Closeout 2018 as past management's failure. Fresh start in 2019.
BioPharmX Reports Third Quarter 2019 Financial Results
MENLO PARK, Calif., Dec. 6, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended Oct. 31, 2018.
During the quarter, newly appointed BioPharmX President and CEO Dr. David S. Tierney commenced a strategic review of the business and took steps to streamline strategy and focus on the company's core products to maximize shareholder value.
Key Highlights
BioPharmX made progress on several fronts:
* In October 2018, BioPharmX initiated its Phase 2b clinical trial of BPX-041, a 1% topical minocycline gel formulation for the treatment of moderate-to-severe papulopustular rosacea. The trial is a randomized, double-blind, vehicle-controlled study in subjects at least 18 years old with 15 to 70 inflammatory lesions and an investigator's global assessment (IGA) score of 3 or 4 (moderate or severe) at baseline. The primary endpoint for the multi-center study is an absolute mean change in the number of inflammatory lesions from baseline to week 12. The company anticipates study completion in mid-2019.
* In November 2018, the company reduced its operating costs by executing a 33% reduction in workforce and discontinuing non-core development programs. As part of this more focused strategy, the company divested its molecular iodine technology, including the dietary supplement product, VI2OLET, thereby allowing the company to focus on its dermatology product candidates.
* In November 2018, the company entered into agreements with certain stockholders to amend certain of its existing warrants to reduce the exercise price per share and to provide for the issuance of new warrants, in exchange for the stockholders' agreement to exercise their existing warrants for cash, resulting in net proceeds to the company of approximately $2.8 million. These proceeds are not reflected in the cash and cash equivalents balance as of Oct. 31, 2018 in the financial tables below.
* In November 2018, NYSE Regulation accepted the company's plan to regain compliance with the NYSE American continued listing standards set forth in the NYSE American Company Guide, and has granted a plan period through Sept. 24, 2019.
"The quarter was important for BioPharmX because we made progress in improving our financial stability and advancing our product pipeline," said Dr. Tierney. "Our operating cost reduction will enable BioPharmX to dedicate more resources to our product candidates."
Third Quarter Financial Results
For the third quarter ended Oct. 31, 2018, total operating expenses were $4.4 million, compared with total operating expenses of $3.7 million in the prior fiscal year's third quarter.
Net loss for the quarter ended Oct. 31, 2018 was $4.4 million, or $0.02 per share, compared with a net loss of $3.7 million, or $0.05 per share, during the prior fiscal year's third quarter.
Excluding stock-based compensation expense and the impact of the change in fair value of warrant liability, non-GAAP net loss for the quarter ended Oct. 31, 2018 was $3.7 million, or $0.02 per share of common stock. During the third quarter of the prior fiscal year, the comparable non-GAAP net loss was $3.3 million, or $0.04 per share.
Cash and cash equivalents as of Oct. 31, 2018, were $3.0 million.